#United States #Class Action #Securities Fraud #Bensalem #Soleno Therapeutics

Investors Can Lead Class Action Against Soleno Therapeutics

In a recent announcement from the Law Offices of Howard G. Smith, shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO) who have suffered financial losses now have the chance to spearhead a class action lawsuit for securities fraud. This legal action arises from allegations that the company failed to adequately disclose critical safety concerns linked to its drug, DCCR, during a crucial clinical trial phase.

What You Need to Know

If you are a shareholder of Soleno who faced losses due to investments made between March 26, 2025, and November 4, 2026, you may be eligible to lead the class action. The deadline to step forward is May 5, 2026. Investors can reach out to Howard G. Smith at his firm to discuss their rights and the details surrounding this lawsuit. The firm has indicated that stakeholders could be misled due to Soleno’s failure to communicate significant safety concerns that arose during the Phase 3 clinical trials.

Allegations Against Soleno Therapeutics

The complaint states that the company downplayed risks associated with DCCR, particularly regarding potential safety issues such as fluid retention observed in clinical trial participants. Furthermore, these misrepresentations led to a false perception about the drug’s commercial viability. The lawsuit contends that Had shareholders been aware of these undisclosed risks, they might not have invested or might have chosen to divest earlier, thereby avoiding significant financial losses.

Notably, there are several critical points outlined in the lawsuit:
1. Downplayed Safety Risks: Soleno allegedly concealed safety issues that could negatively impact users of DCCR.
2. Misleading Statements: Comments made by company executives regarding the drug's potential were said to be materially misleading, lacking a basis in fact.
3. Impact on Share Prices: The obscured risks apparently caused inflated stock valuations, leading to a greater impact on shareholders when the truth was finally revealed.

How to Participate

Affected investors are encouraged to act promptly. Calling the Law Offices of Howard G. Smith at (215) 638-4847 or emailing [email protected] can provide necessary guidance. The office is located at 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania. They offer counsel on whether you may be eligible for the class action and assist with next steps.

The Importance of Legal Action

Participating in a class action lawsuit might be one of the most significant steps a shareholder can take to recover from financial losses, especially when the integrity of a company's communications to investors is called into question. Class actions allow individuals to band together, pooling resources while challenging corporate misbehavior more effectively than might be possible individually.

Remain informed, vigilant, and proactive in addressing the threats posed by possible fraud to safeguard investments. Soleno Therapeutics' case could set precedent for transparency and the safeguarding of investors’ rights in the pharmaceutical sector.

In conclusion, if you have experienced losses with Soleno Therapeutics, don’t miss this opportunity to explore your legal options and possibly recover funds lost in this investment.

Final Thoughts

As this class action develops, it serves as a reminder of the responsibilities companies have towards their shareholders. Transparency is key, and shareholders must remain educated about their rights and options in cases of alleged securities fraud.